Vaxart Inc logo

VXRT - Vaxart Inc Share Price

$1.77 0.1  4.1%

Last Trade - 31/03/20

Sector
Healthcare
Size
Small Cap
Market Cap £96.8m
Enterprise Value £86.0m
Revenue £7.94m
Position in Universe 3800th / 6307
Bullish
Bearish
Unlock VXRT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VXRT Revenue Unlock VXRT Revenue

Net Income

VXRT Net Income Unlock VXRT Revenue

Normalised EPS

VXRT Normalised EPS Unlock VXRT Revenue

PE Ratio Range

VXRT PE Ratio Range Unlock VXRT Revenue

Dividend Yield Range

VXRT Dividend Yield Range Unlock VXRT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VXRT EPS Forecasts Unlock VXRT Revenue
Profile Summary

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated March 14, 1969
Public Since March 17, 1980
No. of Shareholders: n/a
No. of Employees: 28
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 70,734,077
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VXRT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VXRT
Upcoming Events for VXRT
Similar to VXRT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.